Skip to main content

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

Publication ,  Journal Article
Deeg, HJ; Blazar, BR; Bolwell, BJ; Long, GD; Schuening, F; Cunningham, J; Rifkin, RM; Abhyankar, S; Briggs, AD; Burt, R; Lipani, J; Roskos, LK ...
Published in: Blood
October 1, 2001

ABX-CBL, an immunoglobulin M murine monoclonal antibody, recognizes CD147 and initiates cell killing through complement-mediated lysis. In a dose-finding trial, 27 patients with steroid-refractory acute graft-versus-host disease (GVHD) received ABX-CBL at 0.01 (presumed no effect dose), 0.1, 0.2, or 0.3 mg/kg per day, and an additional 32 patients were given ABX-CBL at 0.2 or 0.15 mg/kg per day. All patients had undergone allogeneic transplantation for malignant or nonmalignant disorders and received GVHD prophylaxis, generally with methotrexate- and cyclosporine-containing regimens. None responded to methylprednisolone, given for a minimum of 3 days. ABX-CBL was started 20 to 236 (median, 47) days after transplantation; it was given for 7 consecutive days and was followed by 2 infusions per week for 2 more weeks. Among 51 patients evaluable for efficacy, 26 (51%) responded, including 13 with complete responses (CR) and 13 with partial responses (PR). CR lasting 14 days or longer or PR lasting 7 days or longer occurred in 21 (41%; 8 CR, 13 PR) patients, including 19 of 43 (44%) patients who received 0.1 to 0.3 mg/kg ABX-CBL and 2 of 8 (25%) patients given 0.01 mg/kg per day. Myalgias at doses 0.2 mg/kg or greater were dose limiting and resolved without sequelae. Causes of death included organ failure, progressive GVHD, and infection. No death was attributed to ABX-CBL. At 6 months after the initiation of ABX-CBL therapy, 26 (44%) patients were surviving. These results are encouraging. Further studies on the use of ABX-CBL in the management of GVHD are warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood

DOI

ISSN

0006-4971

Publication Date

October 1, 2001

Volume

98

Issue

7

Start / End Page

2052 / 2058

Location

United States

Related Subject Headings

  • Therapeutic Equivalency
  • Survival Analysis
  • Steroids
  • Middle Aged
  • Membrane Glycoproteins
  • Lymphocyte Subsets
  • Infant
  • Immunology
  • Humans
  • Half-Life
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Deeg, H. J., Blazar, B. R., Bolwell, B. J., Long, G. D., Schuening, F., Cunningham, J., … Heslop, H. E. (2001). Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood, 98(7), 2052–2058. https://doi.org/10.1182/blood.v98.7.2052
Deeg, H. J., B. R. Blazar, B. J. Bolwell, G. D. Long, F. Schuening, J. Cunningham, R. M. Rifkin, et al. “Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.Blood 98, no. 7 (October 1, 2001): 2052–58. https://doi.org/10.1182/blood.v98.7.2052.
Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 1;98(7):2052–8.
Deeg, H. J., et al. “Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.Blood, vol. 98, no. 7, Oct. 2001, pp. 2052–58. Pubmed, doi:10.1182/blood.v98.7.2052.
Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, Rifkin RM, Abhyankar S, Briggs AD, Burt R, Lipani J, Roskos LK, White JM, Havrilla N, Schwab G, Heslop HE. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood. 2001 Oct 1;98(7):2052–2058.

Published In

Blood

DOI

ISSN

0006-4971

Publication Date

October 1, 2001

Volume

98

Issue

7

Start / End Page

2052 / 2058

Location

United States

Related Subject Headings

  • Therapeutic Equivalency
  • Survival Analysis
  • Steroids
  • Middle Aged
  • Membrane Glycoproteins
  • Lymphocyte Subsets
  • Infant
  • Immunology
  • Humans
  • Half-Life